PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

Evaluate the safety and efficacy of PD-1 antibody Carilizumab combined with apatinib for the conversion therapy of unresectable stage III and IV dMMR gastric cancer.

Trial Details

NCT ID
NCT06792162
Phase
PHASE2
Sponsor
Peking University Third Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Carilizumab and Apatinib
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age greater than or equal to 18 years old, gender not limited;
  • Histologically confirmed unresectable stage III and IV dMMR (complete loss of at least one protein, MLH1, PMS2, MSH2, and MSH6), gastric adenocarci…
  • Unresectable gastric cancer patients with potential for conversion therapy, defined as gastric cancer patients with single organ metastasis (such a…
  • Without surgery, radiation therapy, or immunotherapy for the gastric cancer lesion or metastatic tumor.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →